AstraZeneca
- Country
- ๐ฌ๐งUnited Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
- Conditions
- Interventions
- First Posted Date
- 2002-08-05
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 51
- Registration Number
- NCT00042601
- Locations
- ๐ฆ๐บ
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
- Conditions
- Interventions
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 296
- Registration Number
- NCT00042458
- Locations
- ๐บ๐ธ
Grand Rapids Associated Interns, Grand Rapids, Michigan, United States
๐บ๐ธDiablo Clinical Research, Walnut Creek, California, United States
๐บ๐ธPrivate Practice, Lufkin, Texas, United States
Evaluation of the Bioavailability of Pramlintide
- Conditions
- Interventions
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00042471
- Locations
- ๐บ๐ธ
New Orleans Center for Clinical Research, New Orleans, Louisiana, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธDaVita Clinical Research, Minneapolis, Minnesota, United States
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
- First Posted Date
- 2002-06-10
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 336
- Registration Number
- NCT00039013
- Locations
- ๐บ๐ธ
Thomas Jefferson University Diabetes Research Center, Philadelphia, Pennsylvania, United States
๐บ๐ธPhiladelphia Health Associates, Philadelphia, Pennsylvania, United States
๐บ๐ธSt. Agnes Health Care, Baltimore, Maryland, United States
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
- Conditions
- Interventions
- First Posted Date
- 2002-06-10
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 377
- Registration Number
- NCT00039026
- Locations
- ๐บ๐ธ
ANA Ventures, LLC, Mesa, Arizona, United States
๐บ๐ธComprehensive Diabetes-Endocrine Medical Associates, Redwood City, California, United States
๐บ๐ธSt. Agnes Health Care, Baltimore, Maryland, United States
Reversal of Ventricular Remodeling With Toprol-XL
- Conditions
- First Posted Date
- 2002-05-29
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT00038077
- Locations
- ๐บ๐ธ
Research Site, Farmington, Connecticut, United States
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 734
- Registration Number
- NCT00035984
- Locations
- ๐บ๐ธ
Diabetes and Endocrinology Specialists, Chesterfield, Missouri, United States
๐บ๐ธHolston Medical Group, Kingsport, Tennessee, United States
๐บ๐ธUniversity of Mississippi Medical Center, Jackson, Mississippi, United States
CAFE Comparison of Atypicals in First Episode of Psychosis
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00034892
- Locations
- ๐บ๐ธ
Research Site, Dallas, Texas, United States
A Comparison of Seroquel vs. Risperidone in Schizophrenia
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00034905
Iressa Expanded Access Program (EAP)
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00034879
- Locations
- ๐บ๐ธ
Research Site, Cheyenne, Wyoming, United States